Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Significant Increase in Short Interest

Immix Biopharma, Inc. (NASDAQ:IMMX) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 552,800 shares, a growth of 15.2% from the September 15th total of 479,700 shares. Based on an average daily trading volume, of 144,200 shares, the short-interest ratio is presently 3.8 days. Approximately 3.4% of the company’s shares are short sold.

Immix Biopharma Trading Down 1.4 %

NASDAQ:IMMX traded down $0.02 during mid-day trading on Wednesday, hitting $1.44. The company had a trading volume of 98,889 shares, compared to its average volume of 187,247. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $7.75. The business has a fifty day simple moving average of $1.83 and a 200-day simple moving average of $2.10. The firm has a market capitalization of $38.04 million, a price-to-earnings ratio of -1.51 and a beta of 0.12.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. As a group, research analysts anticipate that Immix Biopharma will post -0.64 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Immix Biopharma stock. Tocqueville Asset Management L.P. raised its position in Immix Biopharma, Inc. (NASDAQ:IMMX) by 89.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,800 shares of the company’s stock after buying an additional 17,800 shares during the period. Tocqueville Asset Management L.P. owned approximately 0.14% of Immix Biopharma worth $116,000 at the end of the most recent quarter. Institutional investors own 11.26% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research note on Thursday, October 3rd.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.